Viking Could Surge, but the Bull Case Is Getting Riskier
Viking Therapeutics (NASDAQ:VKTX) has become one of Wall Street’s most tempting biotech stories because its obesity drug could make it a major buyout target. The upside is easy to understand, especially as Medicare access could expand demand for weight loss drugs. But the stock also carries a serious catch: Viking has no approved product yet, … Read more
